This Chart Is Why I'm Not Worried About Guardant Health
Guardant Health (NASDAQ: GH) creates blood tests that inform oncologists of possible treatment options for cancer. It also offers a battery of testing that can alert clinicians to disease recurrence. This is commonly referred to as a liquid biopsy, a blood draw that could potentially replace invasive surgical biopsies.
When cancer survivors are screened for recurrence, the results of this blood draw could mean holding off on the adverse effects of chemotherapy when there is no evidence of disease present. Or the test results could mean having to restart powerful treatment when there is early evidence of recurrence that might not have necessarily shown up with imaging or a surgical biopsy.
So this high-resolution surveillance from the company's blood tests are prolonging and saving lives -- and it's a growing market.
Source Fool.com
